Physician profile
Melchor E Madarang
NPI 1013975366
$4,655.86
in general payments reported to CMS, 2019-2025
39 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $114 · 2021: $279 · 2022: $1,409 · 2023: $1,583 · 2024: $625 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529 · Education: $56.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.27 |
| Education | $56.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $420.87 | 2022-2023 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $412.20 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $291.46 | 2019-2024 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $280.40 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $253.87 | 2022 | |
| Medtronic, INC. | $231.54 | 2022-2024 | Azure Xt Dr Mri Surescan |
| Shockwave Medical, INC | $172.84 | 2022 | |
| Boston Scientific Corporation | $168.16 | 2023 | Watchman Flx |
| Edwards Lifesciences Corporation | $153.50 | 2024 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $151.15 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $150.88 | 2022-2023 | Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $136.33 | 2022-2023 | |
| Dexcom, INC. | $130.81 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Viiv Healthcare Company | $128.69 | 2019-2022 | |
| Horizon Therapeutics Plc | $125.00 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melchor Madarang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.